Clinical Trials Logo

Filter by:
NCT ID: NCT05566054 Recruiting - Newly Diagnosed Clinical Trials

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

Start date: March 1, 2022
Phase: Phase 2
Study type: Interventional

This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed acute monocytic leukemia patients that are ineligible for intensive chemotherapy

NCT ID: NCT05566002 Recruiting - Clinical trials for Pulmonary Hypertension

Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension

AIPHY
Start date: June 1, 2022
Phase:
Study type: Observational

Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.

NCT ID: NCT05565807 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Start date: February 9, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase Ib/IIa, open-label, dose-escalation, and extension study to evaluate the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma.

NCT ID: NCT05565573 Recruiting - Fertility Sparing Clinical Trials

Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia Patients

Start date: November 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

In modern society, endometrial cancer (EC) and atypical hyperplasia is the most frequent desease which can affect the fertility of young patients. For young patients, there is a growing need to treat tumors and fertility sparing. Advaced studies have confirmed thatfertility preservation therapy has better tumor and pregnancy outcomes in specific patients with early gynecological tumors. Clinically, evidence-based guidelines are urgently needed to guide the screening and treatment of women who are suitable for fertility preservation. Fertility-sparing treatment predominantly involves the use of oral progestins and levonorgestrel-releasing intrauterine devices, which have been shown to be feasible and safe in women with early stage EC and minimal or no myometrial invasion. However, data on the efficacy and safety of conservative management strategies are primarily based on retrospective studies.The present study aims to compared the therapeutic effect of Medroxyprogesterone acetate (MPA) and Levonorgestrel-releasing intrauterine system (LNG-IUS) in early-stage endometrioid carcinoma and atypical hyperplasia patients

NCT ID: NCT05565495 Recruiting - Clinical trials for Extracorporeal Membrane Oxygenation

The Effects of ECMO on the Pharmacokinetics of Hydromorphone

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study was to establish a population pharmacokinetic (PPK) model of hydromorphone in patients under ECMO, and to recommend a dosing regimen when the target effective concentration was reached.

NCT ID: NCT05565014 Recruiting - Clinical trials for Malignant Pleural Effusion

Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion

Start date: July 24, 2020
Phase: Early Phase 1
Study type: Interventional

Theory of VAK: 1. Immune cells (T cells for example) of cancer subjects may be domesticated by the tumor microenvironment, and have low efficacy to kill cancer cells. They could be restimulated by virus antigen, and play a powerful tumor killing role while intrapleural to subjects. 2. Releasing of tumor-associated antigen could induce specific anti-tumor immune response. Preparation of VAK: 1. Separate the immune cells and tumor cells from Malignant Pleural and Peritoneal Effusion. 2. Incubate the immune cells with inactivated viruses and tumor cells. 3. Wash to remove impurities. 4. Intrapleural the immune cells to patients

NCT ID: NCT05564897 Recruiting - Bladder Cancer Clinical Trials

Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer

Start date: August 26, 2022
Phase: Phase 2
Study type: Interventional

H101 is an E1B55KD deleted oncolytic adenovirus, which is the first and only adenovirus to be approved by China State Food and Drug Administration in 2005 for treating head and neck cancer. The objective of this phase II clinical trial is to investigate the safety and efficacy of H101 combined with PD-1 inhibitor Camrelizumab in patients with non-muscle-invasive bladder cancer who failed BCG therapy.

NCT ID: NCT05564858 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors

Start date: January 16, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label and two-part study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA022-BB05 in participants with advanced/metastatic solid malignant tumors.

NCT ID: NCT05564819 Recruiting - Postoperative Pain Clinical Trials

Efficacy and Safety of Acetaminophen in Postoperative Pain Management of Infants

Start date: September 14, 2022
Phase: Phase 1
Study type: Interventional

Pain will bring early and long-term adverse reactions to infants. The investigators need to pay attention to whether there is pain in infants after surgery. Since infants cannot self-report pain,The investigators need to use appropriate pain assessment scale to evaluate the pain of these infants, so as to understand the status of postoperative pain in children. The result of pain score not only enables investigators to understand the pain status of children, but also helps investigators to give corresponding intervention and treatment according to the pain degree of children. Postoperative pain management is one of the core contents of ERAS. Effective pain management is beneficial to the early postoperative recovery of infants and reduces the adverse reactions caused by pain. Sveral studies have confirmed that the combination of acetaminophen and opioids could reduce the use of opioids after surgery. But even if opioid use is reduced, it still causes many side effects for children. This study evaluated the safety and efficacy of acetaminophen alone for postoperative analgesia in infants.

NCT ID: NCT05564806 Recruiting - Clinical trials for Advanced Solid Tumors

Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma

Start date: January 31, 2023
Phase: Phase 1
Study type: Interventional

This is an multicenter, open-label, dose-escalation study of the study drug YH004 . The study is designed to determine the safety, tolerability, maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of YH004 in subjects with advanced solid tumors and relapsed or refractory Non-Hodgkin lymphoma.